The roles of uPA/uPAR on the inflammatory osteoclastogenesis
Project/Area Number |
25460078
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Biological pharmacy
|
Research Institution | Doshisha Women's College of Liberal Arts |
Principal Investigator |
KANNO YOSUKE 同志社女子大学, 薬学部, 助教 (40416178)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | uPAR / uPA / LPS / osteoclast / bone / osteoclasts / inflammation |
Outline of Final Research Achievements |
The aim of this study was to clarify the role of uPA/uPAR on the inflammatory bone loss. We found that uPA attenuated inflammatory osteoclastogenesis through the activation of AMPK. Additionally, we found that uPAR regulated inflammatory osteoclastogenesis through the integrin/Akt pathway. Moreover, we found that uPAR regulated inflammation-induced TNF-α production. These data suggest that uPA/uPAR plays an important roles on the inflammatory bone loss.
|
Report
(4 results)
Research Products
(15 results)
-
-
-
-
[Journal Article] Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin.2013
Author(s)
Araki S, Matsuno H, Haneda M, Koya D, Kanno Y, Kume S, Isshiki K, Araki H, Ugi S, Kawai H, Kashiwagi A, Uzu T, Maegawa H.
-
Journal Title
Diabetes Care
Volume: 36(7)
Issue: 7
Pages: e92-e93
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-